Acepodia is a privately held U.S.-Taiwan biotechnology company committed to developing safe, effective, and affordable immunotherapeutic medicines targeting cancers. Acepodia’s proprietary ACC (Antibody Cell-Conjugation) technology platform links tumor targeting antibodies to the proprietary human NK cell line specifically selected for their potent antitumor activity. The ACC technology can be seamlessly combined with currently available antibodies allowing for the rapid development of new targeted therapies in multiple indications, without the need for genetic engineering.